Structure Therapeutics (GPCR) Liabilities and Shareholders Equity (2022 - 2026)

Structure Therapeutics' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 74.04% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $4.7 billion, a 29.88% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 75.34% from the prior year.
• Liabilities and Shareholders Equity slipped to $1.5 billion in Q1 2026 per GPCR's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.6 billion in Q4 2025 and bottomed at $97.8 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $824.3 million (2025), against an average of $722.9 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 392.63% in 2023 and slipped 13.79% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $97.8 million in 2022, then jumped by 392.63% to $482.0 million in 2023, then jumped by 87.41% to $903.3 million in 2024, then soared by 75.34% to $1.6 billion in 2025, then dropped by 4.79% to $1.5 billion in 2026.
• Per Business Quant, the three latest GPCR Liabilities and Shareholders Equity figures stand at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $832.2 million (Q3 2025).